{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:53:50Z","timestamp":1788112430894,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40120-018-0105-0","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T11:05:21Z","timestamp":1531998321000},"page":"233-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia\u2014Key Differences in Pathophysiology and Clinical Management"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5881-3456","authenticated-orcid":false,"given":"Kristen M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"issue":"2\u20133","key":"105_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psychres.2004.10.009","volume":"133","author":"SA Strejilevich","year":"2005","unstructured":"Strejilevich SA, Palatnik A, Avila R, Bustin J, Cassone J, Figueroa S, et al. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res. 2005;133(2\u20133):277\u201380.","journal-title":"Psychiatry Res"},{"issue":"1","key":"105_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"H-W Shin","year":"2012","unstructured":"Shin H-W, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8(1):15\u201321.","journal-title":"J Clin Neurol"},{"issue":"12","key":"105_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","volume":"4","author":"GK Wenning","year":"2005","unstructured":"Wenning GK, Kiechl S, Seppi K, M\u00fcller J, H\u00f6gl B, Saletu M, et al. Prevalence of movement disorders in men and women aged 50\u201389\u00a0years (Bruneck Study cohort): a population-based study. Lancet Neurol. 2005;4(12):815\u201320.","journal-title":"Lancet Neurol"},{"issue":"3","key":"105_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0920-9964(99)00133-4","volume":"42","author":"J Modestin","year":"2000","unstructured":"Modestin J, Stephan PL, Erni T, Umari T. Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res. 2000;42(3):223\u201330.","journal-title":"Schizophr Res"},{"key":"105_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1192\/bjp.181.5.422","volume":"181","author":"J Halliday","year":"2002","unstructured":"Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181:422\u20137.","journal-title":"Br J Psychiatry"},{"issue":"2\u20133","key":"105_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","volume":"19","author":"PN van Harten","year":"1996","unstructured":"van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Cura\u00e7ao Extrapyramidal Syndromes Study: I. Schizophr Res. 1996;19(2\u20133):195\u2013203.","journal-title":"Schizophr Res"},{"issue":"3","key":"105_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00002018-199920030-00006","volume":"20","author":"DC Mamo","year":"1999","unstructured":"Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999;20(3):269\u201375.","journal-title":"Drug Saf"},{"issue":"3","key":"105_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/mds.21854","volume":"23","author":"CD Esper","year":"2008","unstructured":"Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord. 2008;23(3):401\u20134.","journal-title":"Mov Disord"},{"issue":"2","key":"105_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mds.26839","volume":"32","author":"R Savica","year":"2017","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord. 2017;32(2):227\u201334.","journal-title":"Mov Disord"},{"issue":"1","key":"105_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/00002826-199302000-00012","volume":"16","author":"LM Gunne","year":"1993","unstructured":"Gunne LM, Andr\u00e9n PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol. 1993;16(1):90\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"105_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archpsyc.1974.01760130040006","volume":"31","author":"S Snyder","year":"1974","unstructured":"Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry. 1974;31(1):58.","journal-title":"Arch Gen Psychiatry"},{"key":"105_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11940-009-0019-3","volume":"11","author":"F Susatia","year":"2009","unstructured":"Susatia F, Fernandez H. Drug-induced parkinsonism. Curr Treat Options Neurol. 2009;11:162\u20139.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"105_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","volume":"13","author":"PJ Weiden","year":"2007","unstructured":"Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13\u201324.","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"105_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.21188","volume":"22","author":"D Jamora","year":"2007","unstructured":"Jamora D, Lim S-H, Pan A, Tan L, Tan E-K. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22(1):130\u20133.","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"105_CR15","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/00002826-198300061-00004","volume":"6","author":"D Tarsy","year":"1983","unstructured":"Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. 1983;6(Suppl 1):S9\u201326.","journal-title":"Clin Neuropharmacol"},{"issue":"7210","key":"105_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/bmj.319.7210.623","volume":"319","author":"PN van Harten","year":"1999","unstructured":"van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623\u20136.","journal-title":"BMJ"},{"issue":"12","key":"105_CR17","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.4088\/JCP.v69n1204","volume":"69","author":"TD Satterthwaite","year":"2008","unstructured":"Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869\u201379.","journal-title":"J Clin Psychiatry"},{"issue":"2 Suppl","key":"105_CR18","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins, DO et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1\u201356.","journal-title":"Am J Psychiatry"},{"key":"105_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","volume":"51","author":"RJ Hardie","year":"1988","unstructured":"Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson\u2019s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"105_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s007020100006","volume":"108","author":"S Hassin-Baer","year":"2001","unstructured":"Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm. 2001;108(11):1299\u2013308.","journal-title":"J Neural Transm"},{"key":"105_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fpsyt.2018.00018","volume":"9","author":"LE Pieters","year":"2018","unstructured":"Pieters LE, Bakker PR, van Harten PN. Asymmetric drug-induced parkinsonism and psychopathology: a prospective naturalistic study in long-stay psychiatric patients. Front Psychiatry. 2018;9:18.","journal-title":"Front Psychiatry"},{"issue":"3","key":"105_CR22","first-page":"215","volume":"18","author":"SA Bohlega","year":"2013","unstructured":"Bohlega SA, Al-Foghom NB. Drug-induced Parkinson\u2019s disease. Neurosciences. 2013;18(3):215\u201321.","journal-title":"Neurosciences"},{"issue":"S7","key":"105_CR23","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/mds.10573","volume":"18 Suppl 7","author":"W Poewe","year":"2003","unstructured":"Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord. 2003;18 Suppl 7(S7):S16\u201321.","journal-title":"Mov Disord"},{"issue":"3","key":"105_CR24","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s00259-009-1289-4","volume":"37","author":"FJ Diaz-Corrales","year":"2010","unstructured":"Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging. 2010;37(3):556\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"105_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/CBO9781107588738.002","volume-title":"Medication-induced movement disorders","author":"D Kern","year":"2015","unstructured":"Kern D, Lange A. Acute akathisia. In: Friedman J, editor. Medication-induced movement disorders. Cambridge: Cambridge University Press; 2015. p. 3\u201319."},{"issue":"4","key":"105_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3371\/CSRP.3.4.5","volume":"3","author":"C Advokat","year":"2010","unstructured":"Advokat C. A brief overview of iatrogenic akathisia. Clin Schizophr Relat Psychoses. 2010;3(4):226\u201336.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2","key":"105_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/11598540-000000000-00000","volume":"29","author":"JL L\u00f3pez-Send\u00f3n","year":"2012","unstructured":"L\u00f3pez-Send\u00f3n JL, Mena MA, de Y\u00e9benes JG. Drug-induced parkinsonism in the elderly. Drugs Aging. 2012;29(2):105\u201318.","journal-title":"Drugs Aging"},{"issue":"3","key":"105_CR28","first-page":"61","volume":"47","author":"RC Josiassen","year":"2017","unstructured":"Josiassen RC, Kane JM, Liang GS, Burke J, O\u2019Brien CF. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47(3):61\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"105_CR29","doi-asserted-by":"crossref","unstructured":"Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, et al. Confirmed safety of deutetrabenazine for tardive dyskinesia in a 2-year open-label extension study (P4.075). Neurology. 2018;90(15 Supplement). http:\/\/n.neurology.org\/content\/90\/15_Supplement\/P4.075.abstract. Accessed 11 July 2018.","DOI":"10.1212\/WNL.90.15_supplement.P4.075"},{"key":"105_CR30","unstructured":"AUSTEDO [package insert]. North Wales: Auspex Pharmaceuticals; 2017."},{"issue":"4","key":"105_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/089198879400700411","volume":"7","author":"RA Sweet","year":"1994","unstructured":"Sweet RA, Pollock BG, Rosen J, Mulsant BH, Altieri LP, Perel JM. Early detection of neuroleptic-induced parkinsonism in elderly patients with dementia. J Geriatr Psychiatry Neurol. 1994;7(4):251\u20133.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"105_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1176\/jnp.5.1.56","volume":"5","author":"RA Sweet","year":"1993","unstructured":"Sweet RA, DeSensi EG, Zubenko GS. Reliability and applicability of movement disorder rating scales in the elderly. J Neuropsychiatry Clin Neurosci. 1993;5(1):56\u201360.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"105_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"105_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/JPRLS.S99197","volume":"6","author":"P Blanchet","year":"2016","unstructured":"Blanchet P, Kivenko V. Drug-induced parkinsonism: diagnosis and management. J Park Restless Legs Syndr. 2016;6:83\u201391.","journal-title":"J Park Restless Legs Syndr"},{"issue":"12","key":"105_CR35","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917\u201328.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"105_CR36","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","volume":"27","author":"L Citrome","year":"2013","unstructured":"Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879\u2013911.","journal-title":"CNS Drugs"},{"issue":"9","key":"105_CR37","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","volume":"166","author":"S Vinogradov","year":"2009","unstructured":"Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055\u201362.","journal-title":"Am J Psychiatry"},{"key":"105_CR38","unstructured":"Symmetrel [package insert]. Chadds Ford: Endo Pharmaceuticals; 2009."},{"issue":"5","key":"105_CR39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/archpsyc.1976.01770050055008","volume":"33","author":"A DiMascio","year":"1976","unstructured":"DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976;33(5):599.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"105_CR40","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1176\/ajp.133.8.940","volume":"133","author":"W Fann","year":"1976","unstructured":"Fann W, Lake C. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry. 1976;133(8):940\u20133.","journal-title":"Am J Psychiatry"},{"key":"105_CR41","unstructured":"GOCOVRI [package insert]. Emeryville: Adamas Pharma; 2017."},{"key":"105_CR42","unstructured":"Osmolex ER [package insert]. Bridgewater: Vertical Pharmaceuticals; 2018."},{"issue":"5","key":"105_CR43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/mds.20823","volume":"21","author":"D Tarsy","year":"2006","unstructured":"Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21(5):589\u201398.","journal-title":"Mov Disord"},{"issue":"9","key":"105_CR44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1176\/ajp.144.9.1148","volume":"144","author":"PJ Weiden","year":"1987","unstructured":"Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987;144(9):1148\u201353.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"105_CR45","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use. J Clin Psychiatry. 2017;78(3):e264\u201378.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"105_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","volume":"71","author":"SW Woods","year":"2010","unstructured":"Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4):463\u201374.","journal-title":"J Clin Psychiatry"},{"issue":"4 Suppl","key":"105_CR47","first-page":"52S","volume":"8","author":"JM Kane","year":"1988","unstructured":"Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(4 Suppl):52S\u20136S.","journal-title":"J Clin Psychopharmacol"},{"issue":"17","key":"105_CR48","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.1991.03470170090030","volume":"266","author":"BL Saltz","year":"1991","unstructured":"Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991;266(17):2402\u20136.","journal-title":"JAMA"},{"issue":"4","key":"105_CR49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/schbul\/23.4.583","volume":"23","author":"MF Egan","year":"1997","unstructured":"Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23(4):583\u2013609.","journal-title":"Schizophr Bull"},{"key":"105_CR50","doi-asserted-by":"crossref","unstructured":"Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127\u201348, viii.","DOI":"10.1016\/j.ncl.2010.10.002"},{"issue":"389","key":"105_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jns.2018.02.011","volume":"15","author":"CC Zai","year":"2018","unstructured":"Zai CC, Maes MS, Tiwari AK, Zai GC, Remington G, Kennedy JL. Genetics of tardive dyskinesia: promising leads and ways forward. J Neurol Sci. 2018;15(389):28\u201334.","journal-title":"J Neurol Sci"},{"issue":"389","key":"105_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2018.02.005","volume":"15","author":"D Savitt","year":"2018","unstructured":"Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;15(389):35\u201342.","journal-title":"J Neurol Sci"},{"issue":"11","key":"105_CR53","first-page":"1172","volume":"39","author":"MR Munetz","year":"1988","unstructured":"Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39(11):1172\u20137.","journal-title":"Hosp Community Psychiatry"},{"issue":"383","key":"105_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jns.2017.11.019","volume":"15","author":"L Citrome","year":"2017","unstructured":"Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;15(383):199\u2013204.","journal-title":"J Neurol Sci"},{"issue":"4","key":"105_CR55","first-page":"486","volume":"39","author":"NR Schooler","year":"1982","unstructured":"Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"105_CR56","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/NDT.S30767","volume":"9","author":"SK Jankelowitz","year":"2013","unstructured":"Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371\u201380.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"105_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","volume":"80","author":"DD Miller","year":"2005","unstructured":"Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33\u201343.","journal-title":"Schizophr Res"},{"key":"105_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","volume":"389","author":"M Solmi","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21\u20137.","journal-title":"J Neurol Sci"},{"issue":"4 Suppl","key":"105_CR59","first-page":"38S","volume":"8","author":"DV Jeste","year":"1988","unstructured":"Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol. 1988;8(4 Suppl):38S\u201348S.","journal-title":"J Clin Psychopharmacol"},{"issue":"389","key":"105_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","volume":"15","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;15(389):67\u201375.","journal-title":"J Neurol Sci"},{"issue":"11","key":"105_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/070674370505001110","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50(11):703\u201314.","journal-title":"Can J Psychiatry"},{"key":"105_CR62","unstructured":"Ingrezza [package insert]. San Diego: Neurocrine Biosciences; 2017."},{"issue":"5","key":"105_CR63","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","volume":"174","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476\u201384.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"105_CR64","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.4088\/JCP.17m11777","volume":"78","author":"SA Factor","year":"2017","unstructured":"Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia. J Clin Psychiatry. 2017;78(9):1344\u201350.","journal-title":"J Clin Psychiatry"},{"issue":"21","key":"105_CR65","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology. 2017;88(21):2003\u201310.","journal-title":"Neurology"},{"issue":"8","key":"105_CR66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj\u00e4rvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595\u2013604.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"105_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","volume":"33","author":"S Pappa","year":"2010","unstructured":"Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33(6):271\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"105_CR68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","volume":"17","author":"S Angus","year":"1997","unstructured":"Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17(2):88\u201391.","journal-title":"J Clin Psychopharmacol"},{"key":"105_CR69","unstructured":"Prestwick Pharmaceuticals. Tetrabenazine Briefing Document for Peripheral and Central Nervous System Advisory Committee [Internet]. 2007 [cited 2018 May 18]. pp. 1\u2013121. http:\/\/wayback.archive-it.org\/7993\/20180126160441\/https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4328b1-02-Prestwick.pdf. Accessed 11 July 2018."},{"issue":"4","key":"105_CR70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","volume":"130","author":"H Kazamatsuri","year":"1973","unstructured":"Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130(4):479\u201383.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"105_CR71","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","volume":"156","author":"WG Ondo","year":"1999","unstructured":"Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279\u201381.","journal-title":"Am J Psychiatry"},{"key":"105_CR72","unstructured":"Xenazine [package insert]. Washington, DC: Prestwick Pharmaceuticals, Inc.; 2008."},{"issue":"4","key":"105_CR73","first-page":"299","volume":"54","author":"K Ossowska","year":"2002","unstructured":"Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol. 2002;54(4):299\u2013312.","journal-title":"Pol J Pharmacol"},{"issue":"8","key":"105_CR74","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","volume":"17","author":"P Calabresi","year":"2014","unstructured":"Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci. 2014;17(8):1022\u201330.","journal-title":"Nat Neurosci"},{"issue":"4","key":"105_CR75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/14737175.2018.1455504","volume":"18","author":"L Citrome","year":"2018","unstructured":"Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18(4):323\u201332.","journal-title":"Expert Rev Neurother"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-018-0105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-018-0105-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-018-0105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:44:28Z","timestamp":1724413468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-018-0105-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s40120-018-0105-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}